Tag Archives: Adesh Kaul

FDA Approves Basilea’s ZEVTERA® for Severe Bacterial Infections, Including Pediatric Use

(IN BRIEF) Basilea Pharmaceutica Ltd, a biopharmaceutical company, has received approval from the US Food and Drug Administration (FDA) for ZEVTERA® (ceftobiprole medocaril sodium for injection). The approval covers its use in adult patients with Staphylococcus aureus bloodstream infections (bacteremia), … Read the full press release

Basilea Pharmaceutica Reports Strong H1 2023 Financial Results and Increases Full-Year Guidance

(IN BRIEF) Basilea Pharmaceutica Ltd, a biopharmaceutical company specializing in severe bacterial and fungal infection treatments, has announced robust financial results for the first half-year ending June 30, 2023. Their CEO, David Veitch, highlighted the company’s progress in executing their … Read the full press release

Basilea Pharmaceutica Ltd secures non-dilutive refinancing from funds managed by Athyrium Capital Management, LP for its outstanding 2022 convertible bonds

Ad hoc announcement pursuant to Art. 53 LR (PRESS RELEASE) BASEL/ ALLSCHWIL, 7-Sep-2022 — /EuropaWire/ — Basilea Pharmaceutica Ltd (SWX: BSLN), a commercial stage biopharmaceutical company, has announced the company has secured non-dilutive refinancing in the amount of CHF 75 … Read the full press release

Basilea Pharmaceutica Ltd obtient un refinancement non dilutif auprès de fonds gérés par Athyrium Capital Management, LP pour ses obligations convertibles 2022 en circulation

Annonce ad hoc conformément à l’art. 53LR (COMMUNIQUÉ DE PRESSE) BASEL/ ALLSCHWIL, 7-Sep-2022 — /EuropaWire/ — Basilea Pharmaceutica Ltd (SWX : BSLN), une société biopharmaceutique au stade commercial, a annoncé la La société a obtenu un refinancement non dilutif d’un montant … Read the full press release

Adesh Kaul will join Basilea Pharmaceutica’s Management Committee as Chief Corporate Development Officer

BASEL, 05-Mar-2018 — /EuropaWire/ — Basilea Pharmaceutica Ltd. (SIX: BSLN) announced today that Adesh Kaul will join Basilea’s Management Committee as Chief Corporate Development Officer effective March 01, 2018. He will continue to be responsible for strategic planning, business development & … Read the full press release